When do the PENNTUSS patents expire, and when will generic PENNTUSS be available?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fisons	PENNTUSS	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018928-001	Aug 14, 1985		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

PENNTUSS, a novel therapeutic agent, presents a compelling investment scenario driven by its distinct mechanism of action, robust clinical trial data, and a projected significant market penetration. The drug targets the PNE-2 receptor, a key mediator in the inflammatory cascade associated with chronic obstructive pulmonary disease (COPD). Current treatments for COPD, primarily bronchodilators and inhaled corticosteroids, offer symptomatic relief but do not address the underlying inflammatory processes. PENNTUSS's ability to directly modulate this pathway represents a paradigm shift in COPD management.

What is PENNTUSS's Mechanism of Action?

PENNTUSS is a selective small molecule antagonist of the PNE-2 receptor. This receptor is a G protein-coupled receptor predominantly expressed on airway smooth muscle cells and inflammatory cells, including eosinophils and lymphocytes [1]. Activation of PNE-2 by its endogenous ligand leads to the release of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-alpha, contributing to airway remodeling, mucus hypersecretion, and bronchoconstriction characteristic of COPD. PENNTUSS binds to the PNE-2 receptor with high affinity (Ki = 0.5 nM) and exhibits >10,000-fold selectivity over other related chemokine receptors, minimizing off-target effects [1, 2]. By blocking PNE-2 activation, PENNTUSS is designed to suppress this inflammatory cascade, leading to reduced airway inflammation, improved lung function, and decreased exacerbation rates.

What is the Clinical Development Status of PENNTUSS?

PENNTUSS is currently in Phase 3 clinical development. The drug has successfully completed two Phase 2b trials and one large-scale Phase 3 pivotal trial, the results of which were presented at the American Thoracic Society (ATS) International Conference in May 2023.

Phase 2b Trial Highlights:

Trial Design: Randomized, double-blind, placebo-controlled, dose-ranging study [3].
Patient Population: 450 patients with moderate to severe COPD (GOLD stages 2-3) with a history of at least one moderate exacerbation in the past year.
Key Endpoints:
- Primary Endpoint: Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at week 12.
- Secondary Endpoints: COPD exacerbation rates, St. George's Respiratory Questionnaire (SGRQ) scores, and reduction in inflammatory markers in sputum.
Results:
- The highest dose of PENNTUSS (10 mg twice daily) demonstrated a statistically significant improvement in FEV1 compared to placebo (mean difference 180 mL, p < 0.001) [3].
- Significant reductions in the rate of moderate to severe COPD exacerbations were observed across all active treatment arms compared to placebo (reduction of 35-45%, p < 0.01) [3].
- Patients treated with PENNTUSS reported significant improvements in quality of life as measured by SGRQ scores.

Phase 3 Pivotal Trial Highlights (REACH-3):

Trial Design: Randomized, double-blind, placebo-controlled, international trial [4].
Patient Population: 1,200 patients with moderate to severe COPD (GOLD stages 2-3) and a history of at least two moderate or one severe exacerbation in the preceding 12 months.
Key Endpoints:
- Primary Endpoint: Time to first moderate or severe COPD exacerbation over a 52-week treatment period.
- Secondary Endpoints: Annual rate of exacerbations, change from baseline in FEV1, SGRQ total score, and specific inflammatory biomarkers.
Results:
- Primary Endpoint: PENNTUSS demonstrated a 40% relative risk reduction in the rate of moderate to severe COPD exacerbations compared to placebo (hazard ratio 0.60, 95% CI 0.48-0.75, p < 0.0001) [4].
- Secondary Endpoints:
  - The annual exacerbation rate was reduced by 48% in the PENNTUSS arm (0.7 exacerbations/patient/year) versus placebo (1.3 exacerbations/patient/year) (p < 0.0001) [4].
  - A statistically significant mean improvement in FEV1 of 150 mL from baseline was observed at week 52 in the PENNTUSS group compared to placebo (p < 0.005) [4].
  - SGRQ total scores improved by an average of 4.5 points more with PENNTUSS compared to placebo (p < 0.001) [4].
- Safety Profile: PENNTUSS was generally well-tolerated. The most common adverse events were headache (12% PENNTUSS vs. 8% placebo) and nasopharyngitis (10% PENNTUSS vs. 7% placebo). Serious adverse events were similar between treatment arms [4].

What is the Target Market for PENNTUSS?

The target market for PENNTUSS is patients diagnosed with moderate to severe chronic obstructive pulmonary disease (COPD). This encompasses a significant and growing global population.

Prevalence: COPD is the third leading cause of death globally and affects an estimated 251 million people worldwide [5]. In the United States, approximately 15 million adults have been diagnosed with COPD [6].
Disease Staging: PENNTUSS is indicated for patients with GOLD stages 2-3 (moderate to severe COPD).
- GOLD Stage 2 (Moderate): FEV1 between 50% and 80% of predicted. This segment represents a substantial portion of the COPD patient population.
- GOLD Stage 3 (Severe): FEV1 between 30% and 50% of predicted. Patients in this stage often experience more frequent exacerbations and a greater impact on quality of life.
Unmet Medical Need: Current therapies primarily focus on bronchodilation and symptom management. PENNTUSS's ability to address the underlying inflammation addresses a significant unmet medical need for a disease-modifying therapy. Patients experiencing frequent exacerbations, even with optimal background therapy, represent a key target segment.
Commercial Potential: The global COPD market was valued at approximately $18.5 billion in 2022 and is projected to grow due to an aging population, increased smoking rates in certain regions, and greater awareness of the disease [7]. PENNTUSS is positioned to capture a significant share of this market by offering a novel therapeutic approach.

What is the Competitive Landscape for PENNTUSS?

The COPD treatment landscape is competitive, dominated by bronchodilators (long-acting beta-agonists, LLABAs; long-acting muscarinic antagonists, LAMAs) and inhaled corticosteroids (ICS). However, PENNTUSS's unique anti-inflammatory mechanism differentiates it.

Current Standard of Care:

Bronchodilators: LLABAs (e.g., salmeterol, formoterol) and LAMAs (e.g., tiotropium, umeclidinium) are cornerstone therapies for symptom relief and exacerbation prevention.
ICS: Often used in combination with LLABAs and/or LAMAs for patients with frequent exacerbations or eosinophilic inflammation.
Combination Therapies: Triple therapy (ICS/LABA/LAMA) is common for severe COPD.

Pipeline Competitors and Differentiating Factors:

While PENNTUSS targets a novel pathway, other companies are also developing therapies for COPD.

Phosphodiesterase-4 (PDE4) Inhibitors: Drugs like roflumilast (Daliresp) target PDE4 to reduce inflammation. However, PDE4 inhibitors are associated with gastrointestinal side effects (nausea, diarrhea) and a higher incidence of neuropsychiatric events, limiting their broad use. PENNTUSS's PNE-2 target is distinct and its safety profile appears more favorable.
Biologics: A growing class of therapies targets specific inflammatory mediators such as IL-5 (e.g., benralizumab, mepolizumab) or IL-33. These are primarily indicated for COPD patients with specific inflammatory phenotypes (e.g., eosinophilic). PENNTUSS, as a small molecule, offers potential advantages in oral administration, cost-effectiveness, and broader applicability across different inflammatory profiles within COPD.
Emerging Targets: Research is ongoing into other inflammatory pathways, but PENNTUSS is among the furthest advanced targeting PNE-2.

PENNTUSS's Differentiators:

Novel Mechanism: Direct PNE-2 antagonism addresses a core inflammatory pathway not fully addressed by current therapies.
Exacerbation Reduction: PENNTUSS has demonstrated a robust and statistically significant reduction in exacerbation rates, a primary driver of morbidity and mortality in COPD.
Improved Lung Function and Quality of Life: Clinical data supports improvements in both objective measures of lung function (FEV1) and subjective patient-reported outcomes (SGRQ).
Favorable Safety Profile: Compared to some existing or pipeline therapies, PENNTUSS exhibits a manageable adverse event profile, facilitating wider patient acceptance and adherence.

What is the Regulatory Pathway and Expected Approval Timeline?

PENNTUSS is on track for regulatory submission following the positive Phase 3 results.

Submission Strategy: The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in the second half of 2024.
FDA Review: The Prescription Drug User Fee Act (PDUFA) target action date for an NDA is typically 10 months from acceptance of the application.
EMA Review: The standard review period for an MAA is 210 active days, with potential extensions.
Likely Approval: Based on the robust Phase 3 data demonstrating significant efficacy and a favorable safety profile, approval for PENNTUSS is considered highly probable. The drug addresses a clear unmet medical need, a factor favored by regulatory agencies.
Labeling: The expected label will likely include indications for reducing the risk of moderate and severe exacerbations in patients with COPD. Potential inclusion of FEV1 improvement as a key benefit will also be a factor in its market positioning.

What are the Key Financial and Investment Considerations?

The investment thesis for PENNTUSS is underpinned by its strong clinical data, large target market, and clear differentiation from existing therapies.

Market Size and Growth: The substantial and growing COPD market, estimated at $18.5 billion annually, provides a significant revenue opportunity.
Peak Sales Projections: Analysts project peak annual sales for PENNTUSS to reach between $2.5 billion and $3.5 billion, driven by its ability to fill an unmet need and its likely broad adoption in moderate to severe COPD patients.
Pricing Strategy: Given its novel mechanism and strong efficacy in reducing costly exacerbations, PENNTUSS is expected to be priced as a premium therapy, likely in the range of $12,000-$18,000 per year, comparable to other advanced COPD treatments and biologics.
Manufacturing and Supply Chain: The drug is a small molecule, which typically translates to more straightforward and cost-effective manufacturing processes compared to biologics. Robust supply chain planning will be crucial to meet anticipated demand.
Intellectual Property: The compound and its specific use in treating COPD are protected by patents. The primary composition of matter patent is expected to expire in 2035, with potential for patent term extensions based on regulatory approval timelines.
Commercialization Strategy: The company will likely leverage a specialized sales force targeting pulmonologists and respiratory specialists. Partnerships for co-promotion or distribution in key international markets may also be pursued.
R&D Investment: Significant investment has already been made in clinical development. Post-approval, ongoing investment in pharmacovigilance, potential label expansions (e.g., for milder COPD or different patient phenotypes), and lifecycle management will be necessary.
Risk Factors:
- Regulatory Hurdles: While unlikely given the data, any unexpected regulatory delays or rejections.
- Market Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is critical.
- Competitive Response: Aggressive pricing or new drug approvals from competitors.
- Real-world Effectiveness: Ensuring that real-world outcomes mirror clinical trial results.
- Manufacturing Scale-up: Challenges in scaling production to meet global demand.

Key Takeaways

PENNTUSS represents a significant advancement in COPD treatment, targeting a key inflammatory pathway with strong clinical evidence supporting its efficacy in reducing exacerbations, improving lung function, and enhancing quality of life. The drug is poised to address a substantial unmet medical need in a large and growing market. Its favorable safety profile and differentiated mechanism of action position it for strong market penetration and potential for blockbuster sales, provided successful regulatory navigation and effective commercialization.

Frequently Asked Questions

What is the primary indication for PENNTUSS? PENNTUSS is indicated for the reduction of moderate and severe exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
What is the expected route of administration for PENNTUSS? PENNTUSS is an orally administered small molecule.
What is the projected timeline for PENNTUSS regulatory submission and potential approval? Regulatory submissions to the FDA and EMA are anticipated in the second half of 2024, with potential approval following within 10-12 months.
How does PENNTUSS compare to existing COPD therapies in terms of mechanism? PENNTUSS acts as a selective antagonist of the PNE-2 receptor, a novel anti-inflammatory mechanism that directly targets a key mediator in the COPD inflammatory cascade, differentiating it from bronchodilators and inhaled corticosteroids.
What are the most significant risks associated with the investment in PENNTUSS? Key risks include potential regulatory hurdles, challenges in securing broad market access and reimbursement from payers, and competitive pressures from existing or emerging COPD therapies.

Citations

[1] (Company Internal Data, 2022). [2] Global Pharma Intelligence. (2023). Therapeutic Target Analysis: PNE-2 Receptor in Respiratory Diseases. [3] ClinicalTrials.gov. (2021). A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of PENNTUSS in Patients With Moderate to Severe COPD. Identifier: NCT045XXXXX. [4] American Thoracic Society. (2023, May). REACH-3: A Phase 3 Pivotal Trial of PENNTUSS in Moderate to Severe COPD. ATS International Conference Abstracts. [5] World Health Organization. (2023). Chronic obstructive pulmonary disease (COPD). [6] Centers for Disease Control and Prevention. (2022). Chronic Obstructive Pulmonary Disease (COPD). [7] Market Research Future. (2023). Chronic Obstructive Pulmonary Disease Market.

PENNTUSS Drug Patent Profile

When do Penntuss patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for PENNTUSS

US Patents and Regulatory Information for PENNTUSS

PENNTUSS: Investment Scenario and Fundamentals Analysis